PCR

In light of the recent Patient Capital Review (PCR), and next week’s Autumn Budget,  Enterprise Investment Scheme (EIS) and Venture Capital Trust (VCT) providers are concerned that their industry could be under threat. Perhaps the greatest impact could be  that next week’s budget will target asset-backed investments, and remove them from permissible EIS and VCT allocations. These were some of the key talking points at Intelligent Partnership’s EIS and VCT showcase at the London Stock Exchange on 14 November. The event, which is a genuine chance for advisers to compare managers, was a valuable opportunity for more than 100 industry… continue reading